MARKET

KPRX

KPRX

KIORA PHARMACEUTICALS INC
NASDAQ
1.910
0.000
0.00%
Opening 11:20 12/30 EST
OPEN
1.940
PREV CLOSE
1.910
HIGH
1.940
LOW
1.910
VOLUME
5.32K
TURNOVER
--
52 WEEK HIGH
4.180
52 WEEK LOW
1.765
MARKET CAP
7.02M
P/E (TTM)
-0.9295
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KPRX last week (1222-1226)?
Weekly Report · 1d ago
Weekly Report: what happened at KPRX last week (1215-1219)?
Weekly Report · 12/22 10:25
Weekly Report: what happened at KPRX last week (1208-1212)?
Weekly Report · 12/15 10:33
Weekly Report: what happened at KPRX last week (1201-1205)?
Weekly Report · 12/08 10:32
Kiora Pharmaceuticals Secures New US Patent to Expand Delivery Options for Eye Drug KIO-104
Benzinga · 12/01 12:11
Kiora Pharmaceuticals Granted U.S. Patent for Novel KIO-104 Anti-Inflammatory Formulations
Reuters · 12/01 11:46
Weekly Report: what happened at KPRX last week (1124-1128)?
Weekly Report · 12/01 10:27
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 11/28 21:06
More
About KPRX
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.

Webull offers Kiora Pharmaceuticals Inc stock information, including NASDAQ: KPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KPRX stock methods without spending real money on the virtual paper trading platform.